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Abstract: Aim: Increased cardiovascular risk after use of selective or nonselective cyclooxygenase-2 (COX-2)-inhibitors 
might partly be caused by enhanced platelet aggregability. However, an effect of COX-2 inhibition on platelets has so far 
not been observed in humans.  
Methods: We tested in healthy volunteers the effect of COX-2-inhibition nearly in-vivo, i.e. immediately after and even 
during blood sampling.  
Results: Measurement within 2 minutes after venipuncture, but not 60 minutes later, showed that 50 mg of rofecoxib 
(n=12) or 500 (n=8) or 1000 (n=8) mg of aspirin increased ADP-induced platelet aggregation in a whole-blood aggre-
gometer to, respectively, 152, 176 and 204 % of basal level (p<0.01). No significant differences in aggregability were  
observed after ingestion of 80 mg of aspirin (n=16), or placebo (n=8). Plasma 6-keto-PGF1 was decreased to 74 % after 
rofecoxib and to 76 and 70 % after 500 and 1000 mg of aspirin but did not change after low dose aspirin. Continuous  
photometrical measurement of aggregation in blood flowing from a cannulated vein revealed that high dose aspirin did not 
elicit aggregation by itself, but increased ADP-induced aggregation in proportion to the decrease in prostacyclin formation 
(r=0.68, p = 0.004). Since in these experiments thromboxane production was virtually absent, the enhanced aggregation 
after partial COX-2 inhibition was not caused by unopposed thromboxane formation.  
Conclusions: We conclude that both selective and nonselective COX-2 inhibition enhances ADP-induced platelet   
aggregation in humans. This effect can only be detected during or immediately after venipuncture, possibly because of the 
short half-life of prostacyclin. 
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INTRODUCTION  
  Inhibitors of cyclooxygenase-2 (COX-2) are reported to 
promote cardiovascular events in patients at atherothrom-
botic risk. Recent studies have shown that this effect is not 
specific for selective COX-2 inhibitors but has been demon-
strated for nonselective COX-2 inhibitors as well [1-6]. The 
mechanisms involved remain unclear. In rats we have found 
that both selective (parecoxib) and nonselective (high dose 
aspirin) COX-2 inhibitors enhance shear stress-induced 
platelet aggregation when measured nearly in-vivo, i.e. in an 
extracorporeal shunt between carotid and femoral artery [7]. 
However, the hypothesis that COX-2 inhibition increases 
platelet aggregability also in humans seems to be contra-
dicted by clinical and laboratory studies [8-15].  
  In these studies the time between blood sampling and 
aggregation-testing was, as usual in the clinical setting, one 
hour or more. During that time the reaction of platelets to 
ADP and collagen increases, reaching a stabile maximum 
after 30 to 45 minutes [16]. This may seriously hamper and 
even preclude detection of an increase in platelet aggregability 
at one hour or more after venipuncture. Moreover, COX-2  
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derived endogenous platelet antagonists with a short half-
life, such as prostacyclin (PGI2), which inhibits platelet ag-
gregation with a half-time of 6 – 10 minutes in human blood 
and 11 to 16 minutes in human plasma [17-19], will then 
have lost their effect. Therefore, we compared in humans the 
effects of COX-2 inhibition on platelet aggregability at 2 and 
at 60 minutes after blood sampling, using a conventional 
whole-blood aggregometer. To approach the in-vivo situation 
even more, aggregation was in a number of experiments also 
measured directly in blood flowing from a cannulated vein, 
with aid of an established photometric device [20].
 In addi-
tion, we measured circulatory levels of a stabile metabolite 
of PGI2 before and after COX-2 inhibition. 
MATERIALS AND METHODS 
Subjects and Protocol 
  Healthy non-smoking Caucasian volunteers (aged 20-62 
years), who did not use drugs for at least two weeks before 
enrolment, and who did not exercise, eat fish or drink alco-
hol within the 12 hours before the experiment, gave in-
formed consent. To reduce the influence of hormonal varia-
tion only male subjects were involved, and the effect of cir-
cadian variation in platelet aggregability was minimised by 
starting all experiments at 11.00 h am, when aggregation is 
maximal [21]. The effect of selective COX-2 inhibition on COX-2 Inhibition Enhances Platelet Aggregation  The Open Cardiovascular Medicine Journal, 2010, Volume 4    199 
ADP-induced platelet aggregation was studied by testing 
aggregation before and 1.5 – 2 hours after intake of placebo 
(n=8) or 50 mg of rofecoxib (VIOXX, Merck, Sharp and 
Dohme, now withdrawn from the market, n=12), which is 
the recommended dose for relief of acute pain. It reduces 
COX-2 activity within 1.5 hour after ingestion for at least 10 
hours [22], and has no significant effect on COX-1 activity 
[23]. For nonselective COX-2 inhibition high dose aspirin 
(Aspro, Bayer) was used in a dose of 500 mg (n=8) or 1000 
mg (n=8). Aspirin was also given in low dose: 80 mg (Car-
dio 80 PCH, n=16). Low dose aspirin blocks COX-1 medi-
ated platelet thromboxane-A2 (TXA2 ) formation within 20 
minutes after ingestion. The blockade lasts for the life-time 
(approximately 10 days) of the platelets, because they lack 
the ability to make new protein. The inhibiting effect of low 
dose aspirin on COX-2 mediated prostacyclin formation in 
the nucleated endothelial cells is only short-lasting because 
of  protein  resynthesis, whereas high dose aspirin reduces 
endothelial PGI2 synthesis for more than 3 hours [24]. Plate-
let aggregation was elicited by ADP because ADP plays a 
central role in initiating and propagating aggregation induced 
by a variety of agonists, and because ADP-induced aggrega-
tion is known to be inhibited by PGI2 [25]. The study proto-
col was approved by the Medical Ethics Review Committee 
of our hospital.  
Blood Collection 
  Blood was collected via an indwelling plastic cannula in 
an antecubital vein. Because of the possible generation of 
prostacyclin and other substances that affect platelet activity 
during cannulation, the first few milliliters were discarded. 
Part of the blood was added to 3.2 % sodium citrate (9:1 
volume ratio) for in-vitro measurement of platelet aggrega-
bility, and another part immediately added to a solution of 
K3-EDTA for measurement of PGI2 levels (see Measure-
ment of prostanoids), and for platelet and other blood cell 
counts (ABX Diagnostics, Netherlands). 
Platelet Aggregation In-Vitro 
  To enable immediate measurement of aggregation in-
vitro, blood was collected into a prewarmed syringe and 
quickly added to a whole-blood aggregometer (Chronolog 
Corporation, Havertown). Aggregation was elicited by 5 μM 
ADP within exactly 2 minutes after blood collection, and 
quantified as the change in impedance (ohms) at 6 minutes 
after addition of the agonist. Only one agonist could be 
tested in this way, because the aggregometer had only one 
channel. The unused blood was set apart at room temperature 
(in an air-free syringe, to prevent loss of CO2 and change of 
pH), and tested 60 minutes later. After the latter test the reac-
tion to 330 μM arachidonic acid was measured as well. In a 
separate set of experiments (n=8) the time-dependency of the 
platelet reaction to 5 μM ADP was more precisely studied by 
varying the delay between venipuncture and in-vitro aggre-
gation testing (between 2 and 60 minutes) in subjects who 
had not taken COX-inhibitors. 
Platelet Aggregation in Flowing Blood 
  In the experiments with high dose aspirin aggregability 
was measured both in-vitro (see above) and nearly in-vivo by 
a photometric device that can detect platelet aggregates in 
flowing blood. For the latter measurement the venous can-
nula was via tubing connected to a glass capillary on the 
stage of a microscope. Passing platelet aggregates caused a 
change in light transmission, which was, after 40 x magnfi-
cation, projected on light-sensitive diodes. The rectified and 
integrated signal was continuously measured [20]. Blood 
flow through the capillary was stabilized at 2 ml/min by a 
small home-made roller pump. Premature platelet activation 
and clotting were prevented by coating the tubing with al-
bumin and by infusing unfractionated heparin (final concen-
tration 5 IE/ml blood) into the line before the pump.  
  Platelet aggregability in flowing blood was tested within 
15 seconds after the blood left the body, by two-minute infu-
sions into the tubing of incremental concentrations of ADP 
(10, 20, 30, 40, and 50 μM final concentration). This was 
followed by a two-minute infusion of 20 μM epinephrine. 
During platelet aggregation, induced by 30 μM ADP, blood 
was collected from the end of the tubing in K3-EDTA solu-
tion for assessment of plasma TXA2 (see Measurement of 
prostanoids). 
Measurement of Prostanoids 
  For enzymeimmunoassays of plasma 6-keto-PGF1  and 
TXB2, which are the stabile metabolites of PGI2 and TXA2, 
respectively, EDTA-blood was centrifuged at 3500 g for 20 
minutes and the platelet poor plasma stored in –80 °C until 
analysis by EIA Biotrak systems (Amersham Biosciences, 
detection limits: 3.0 and 3.6 pg/ml , respectively). Before 
analysis the prostaglandins were separated from fatty acids 
using Amprep 
TM minicolumns and solvent extraction, ac-
cording to the manufacturer's instructions. Samples selected 
for measurement of 6-keto-PGF1 were divided before analy-
sis and one part was spiked with 6-keto-PGF1 for estima-
tion of recovery. All assays were performed in duplicate.  
Statistics 
  Values are given as mean±standard error of the mean 
(SEM). The effects of selective or nonselective COX-2 inhi-
bition on the amount of platelet aggregation at different time 
points (in the whole-blood aggregometer), or for several 
doses of ADP (in flowing blood), were analysed by two-way 
ANOVA for repeated measurements, followed by a Bonfer-
roni test. Plasma levels of PGI2 and TXA2 metabolites were 
compared with one-way ANOVA or the paired t-test. Statis-
tical significance was set at P<0.05.
  
RESULTS 
Platelet Aggregation In-Vitro 
  Measurement of aggregation at two minutes after blood 
collection showed that ingestion of a single dose of 50 mg 
rofecoxib, in contrast to placebo, caused an increase in ADP-
induced platelet aggregation (to 152 % of basal value, Fig. 1 
and Table 1). This increase could not been observed at 60 
minutes after venipuncture. The selectivity of rofecoxib as 
COX-2 inhibitor was demonstrated by an unchanged reac-
tion to arachidonic acid (Table 1).  
  Comparable results were found with nonselective COX-
inhibition by high dose aspirin. Whereas low dose aspirin 
(80 mg) had no effect, higher doses of aspirin (500 and 1000 200    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Borgdorff
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mg) elicited a similar increase in aggregation as rofecoxib 
did (Fig. 2 and Table 1). This was, again, demonstrable only 
when aggregation was measured immediately after blood 
sampling, but not when the blood was set apart and aggrega-
tion elicited 60 minutes later. Reactions to arachidonic acid 
(measured only after more than 60 minutes) were suppressed 
by all doses of aspirin (Table 1).  
  Time-dependency of the in-vitro platelet reaction to ADP 
in subjects who had not taken COX-inhibitors is depicted in 
Fig. (3). Platelet aggregability (y) increased with the delay 
between venipuncture and aggregation testing (x) according 
to y= 8.75 - 6.73·e 
-0.079·
x , and reached a plateau at about 45 
minutes. The time to reach half the maximal value was 8.8 
minutes. The level at 60 minutes was similar for arachidonic- 
and for ADP-induced aggregation (Table 1), suggesting a 
maximal response, and illustrating the necessity to measure a 
possible increase in aggregability not at 60 minutes but 
quickly after venipuncture. 
Platelet Aggregation in Flowing Blood 
  The rather unexpected findings with high dose aspirin 
were corroborated by testing platelet aggregability directly in 
blood flowing from a cannulated vein. In unstimulated blood 
no spontaneous platelet aggregation was detected, neither in 
control nor after aspirin ingestion. This indicates that high 
dose aspirin by itself did not elicit aggregation. In accor-
dance, platelet counts were not significantly diminished (261 
± 14 x 10
9/L versus 275 ± 12 x 10
9/L in control), and other 
cell counts remained within normal ranges (not shown). Ad-
dition of ADP elicited a dose-dependent increase in aggrega-
tion (for an example see Fig. 4A). These responses were en-
hanced to 160 ± 20 % of control ((p<0.0001, Fig. 4B) after 
 
 
 
 
 
 
 
 
 
Fig. (1). Effect of placebo (A, n=8) and selective COX-2 inhibition by a single oral dose of 50 mg rofecoxib (B, n=12) on ADP-induced 
platelet aggregation in a conventional whole-blood aggregometer. Enhancement by selective COX-2 inhibition is demonstrable at two  
minutes after blood collection, but not when the blood is set apart for 60 minutes. Means ± SEM of maximal value in ohms after application 
of 5 μM ADP. ** = p<0.01, ns = not significant. 
Table 1.  Effect of a Single Dose of Rofecoxib (50 mg) or Aspirin on In-Vitro Platelet Aggregation in a whole Blood Aggregometer 
at 2 and 60 Minutes after Blood Sampling 
Placebo Rofecoxib  Aspirin 
                           at 
     80 mg  500 mg  1000 mg 
c     3.1 ± 0.4  c     3.4 ± 0.5  c     3.5 ± 0.4  c     3.3 ± 1.0  c     2.5 ± 1.0  ADP 
 
2 min 
       3.0 ± 0.4         5.2 ± 0.8 **         3.0 ± 0.4         5.8 ± 1.3 *         5.1 ± 1.2 * 
c     9.5 ± 0.5  c     10.4 ± 0.5  c     10.1 ± 0.5  c     9.3 ± 1.6  c     10.4 ± 1.6  ADP 60  min 
       8.8 ± 0.9         11.1 ± 0.6         8.6 ± 0.5         8.3 ± 1.4         10.4 ± 1.0 
c     10.4 ± 0.5  c     10.8 ± 0.6  c     10.9 ± 0.7  c     11.5 ± 0.9  c      9.9 ± 1.2  Arach. 
Acid         9.4 ± 0.6         11.3 ± 0.7        1.1 ± 0.3 **         1.1 ± 0.7 **          0.2 ± 0.2 ** 
n 
60 min 
             8                12             16               8                8 
Maximal reactions to ADP (5μM) and arachidonic acid (333μM) in ohms (means ± SEM). c = control condition before ingestion of the study drug. * = p<0.05 and ** = p<0.01, 
compared to control. COX-2 Inhibition Enhances Platelet Aggregation  The Open Cardiovascular Medicine Journal, 2010, Volume 4    201 
ingestion of high dose aspirin, without a significant differ-
ence between experiments with 500 or with 1000 mg of aspi-
rin. This enhancement was unlikely caused by unopposed 
TXA2 activity, because TXA2-generation during ADP-
induced platelet aggregation in flowing blood was markedly 
reduced after aspirin (from 552 ± 96 to 30 ± 7 pg/ml, p < 
0.0001).  
 
 
 
 
 
 
 
 
 
Fig. (3). Time-dependent increase of ADP-induced platelet aggre-
gation after venipuncture. Means ± SEM of maximal value in ohms 
after application of 5 μM ADP to whole blood. Half-time of the 
fitted curve was 8.8 minutes. Blood was collected from subjects 
(n=8) who had not ingested a COX-2 inhibitor, and was kept in 
closed tubes at room temperature. 
  Also reactions of the platelets to 20 μM of epinephrine, 
injected after the series of ADP additions, tended to be 
stronger after high dose aspirin (146 ± 22 % of control, 
p=0.09).  
Prostacyclin 
  Basal levels of plasma 6-keto-PGF1  , the stabile me-
tabolite of prostacyclin, were reduced after a single dose of 
rofecoxib (to 74 %) and after the higher doses of aspirin (to 
76 % after 500 mg and to 70 % after 1000 mg), but not after 
low dose aspirin (to 98 %) (Fig. 5). When aggregation was 
tested in flowing blood, a positive correlation (Pearson 
r=0.68, p = 0.004) was found between the individual amount 
of 6-keto-PGF1 reduction and the aspirin-induced increase 
of platelet aggregation (averaged for the five doses of ADP).  
DISCUSSION 
  This study shows that both selective and nonselective 
COX-2 inhibition by, respectively, rofecoxib or high dose 
aspirin enhances ADP-induced platelet aggregation in 
healthy humans. This enhancement was demonstrable only 
with near-in-vivo measurement of platelet aggregation in 
blood flowing from a cannulated vein, or in-vitro with a 
whole blood aggregometer, if aggregation was tested within 
the first minutes after blood sampling, but not if the blood 
was set apart and the measurements postponed for one hour. 
The present study extends previous findings of increased 
platelet aggregability after COX-2 inhibition in rats [7], and 
is in line with studies showing increased platelet adhesion in 
hamster arterioles [26] and rabbit injured carotid arteries 
[27], after COX-2 inhibition. 
COX-2 Inhibition and Increased Thrombotic Risk 
  During measurement of platelet aggregation in blood 
flowing from a cannulated vein no aggregates were detected 
as long as platelets were not stimulated by an exogenous 
agonist, neither in control nor after partial COX-2 inhibition 
by aspirin. Therefore, COX-2 inhibition did not by itself 
elicit platelet aggregation. This suggests that inhibition of 
COX-2 in healthy man is of limited risk. In cardiovascular 
patients, however, COX-2 inhibition might amplify aggrega-
tion elicited by e.g. rupture of an atherosclerotic plaque or 
further narrowing of a vascular stenosis.  
  The results with an adult dose of aspirin (500-1000 mg) 
contrasts to the well known beneficial effect of low dose 
aspirin in preventing restenosis. It might, however, explain 
why in the Cottbus study significantly more reinfarctions 
were seen with 1000 mg of aspirin per day than with 30 or 
60 mg/day [28]. Also more recent studies showed that the 
risk of stroke, myocardial infarction, and death was signifi-
cantly greater for patients taking higher doses of aspirin 
(650-1300 mg) compared to those taking lower doses (81-
325 mg) [29-32]. The results with high dose aspirin show at 
the same time that it is not the selectivity of COX-2 inhibi-
tors that makes them prothrombotic. This could explain why 
cardiovascular risk is also increased by use of nonselective 
COX inhibitors like ibuprofen and diclofenac (hazard ratios 
of, respectively, 1.51 and 1.63 [2-6]).  
 
 
 
 
 
 
Fig. (2). Effect of a single oral dose of 80 mg (A, n=16), 500 mg (B, n=8), and 1000 mg (C, n=8) of aspirin on ADP-induced platelet  
aggregation in a conventional whole-blood aggregometer. Enhancement by the higher doses of aspirin (nonselective COX-2 inhibition) is 
demonstrable at two minutes after blood collection, but not when the blood is set apart for 60 minutes. Means ± SEM of maximal value in 
ohms after application of 5 μM ADP. ** = p<0.01, ns = not significant. 202    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Borgdorff
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Time-Dependency of Platelet Aggregation 
 Our  near  in-vivo measurements explain why the stimulat-
ing effect of COX-2 inhibition on platelet aggregation has 
not been detected in clinical settings where measurements 
are usually delayed by transport of the blood samples to a 
local laboratory [8-15]. Hence, our findings show that impor-
tant information about the thrombotic risk of a patient may 
be missed when aggregation is not measured immediately 
after venipuncture.  
  A time-dependent increase of platelet aggregability after 
venipuncture (see our Fig. 3) has been found earlier by other 
investigators using whole blood analysers [16] or flow cy-
tometry [33],
 indicating that the method used is irrelevant. 
Inoue et al. [34],
 using the screen filtration method, found 
that an enhancing effect of cigarette smoking on platelet   
aggregation was demonstrable only at 5 minutes, but not at 
60 minutes. These findings are compatible with our results, 
particularly because smoking is, just as COX-2 inhibition, 
known to inhibit PGI2 formation [35].
  
  The mechanism for the time-dependent increase in plate-
let aggregability after venipuncture awaits to be clarified. It 
has been postulated that the increase is caused by a tempera-
ture-dependent change in the intra-platelet calcium level 
[16], or by degradation of labile platelet inhibitors like PGI2, 
EDRF/NO and ecto-ADPases.  
Thromboxane A2 is not Essential for the Enhancement of 
ADP-Induced Platelet Aggregation by COX-2 Inhibition 
  A common hypothesis states that selective COX-2 inhibi-
tors might be prothrombotic by inhibiting prostacyclin for-
mation while leaving COX-1 induced thromboxane forma-
tion unopposed, in this way disturbing the balance between 
suppression and promotion of aggregation [26]. In our ex-
periments with high dose aspirin, however, thromboxane 
formation was nearly abolished. Hence, the increase of ADP-
induced aggregation in these experiments was not an effect 
of unopposed TXA2 formation. This might be explained by 
the fact that thromboxane plays a minor role only in ADP-
 
 
 
 
 
 
 
 
 
Fig. (4). A. Platelet aggregation in flowing blood is induced by infusion of increasing concentrations of ADP into tubing connected to a  
cannulated vein. The aggregates were detected photometrically when they passed a glass capillary connected to the tubing. Raw signals  
are rectified and integrated over periods of ten seconds. A.u.: arbitrary units. B. Platelet aggregation measured directly in flowing blood is 
enhanced by ingestion of a high dose of aspirin (pooled data for 500 and 1000 mg). Means ± SEM represent the total amount of aggregation 
during two minutes of ADP-infusion, before and after high dose aspirin. * = p<0.05. Overall difference between aspirin and control: 
p<0.0001. 
 
 
 
 
 
 
 
Fig. (5). Effect of a single dose of 50 mg of rofecoxib (A, n=12) and of aspirin in doses of 80 mg (B, n=16), 500 mg (C, n=8), and 1000 mg 
(D, n=8) on plasma levels of 6-keto-PGF1. Means ± SEM. * = p<0.05. COX-2 Inhibition Enhances Platelet Aggregation  The Open Cardiovascular Medicine Journal, 2010, Volume 4    203 
induced aggregation [36, 37]. Although in the clinical situa-
tion also TXA2 –dependent agonists will be involved, various 
studies showed that the risk of myocardial infarction was not 
reduced when the use of a selective COX-2 inhibitor was 
combined with low dose aspirin [5, 38]. 
Possible Role of Prostacyclin 
  Selective or nonselective COX-2 inhibition by a single 
dose of respectively rofecoxib or high dose aspirin reduced 
the plasma PGI2 levels by 24 to 30 %. Although this reduc-
tion may seem moderate, ADP-induced platelet aggregation 
was enhanced by 52 to 60 %. It might be speculated that this 
enhancement will be even stronger with daily use of COX-2 
inhibitors. Measurement of aggregation in blood flowing 
from a cannulated vein furthermore revealed a significant 
correlation between the increase in aggregation and the   
degree of PGI2 reduction. These results give for the first   
time direct evidence for the hypothesis of Moncada and 
Vane [39], i.e. that the basal level of circulating endogenous 
PGI2 is sufficiently high to partially depress platelet aggrega-
tion in human blood. This hypothesis was rejected in earlier 
studies, with the argument that the PGI2-levels in circulating 
blood are too low to influence platelet aggregability [40]. 
Table 2 shows, however, a number of studies in which levels 
of PGI 2 were found comparable to those found in the present 
study.  
  The inhibiting influence of PGI2 on platelets has been 
thought to occur via stimulation of platelet adenylate cyclase 
and elevation of platelet cAMP, which reduces intracellular 
levels of free calcium [41-43].  
  Our finding that COX-2 inhibition did not by itself elicit 
platelet aggregation complies with the absence of spontane-
ous thrombosis in mice lacking receptors for PGI2 [44], and 
the observation of Arehart et al. [45] in patients with a natu-
rally occurring mutation in the prostacyclin receptor. These 
authors conclude that a deficiency in prostacyclin signaling 
is not likely an initiating factor in cardiovascular disease but 
accelerates the course of disease in those patients with the 
greatest risk factors.  
  Reduction of PGI2 synthesis is not exclusively caused by 
use of selective or nonselective COX-2 inhibitors, or by 
smoking, but may also occur in several diseases, including 
diabetes [46], or might result from use of medicines, e.g. 
inhibitors of vascular endothelial growth factor (VEGF) in 
cancer patients [47].
 In addition, plasmatic half-life of PGI2 
is significantly shortened during severe infections, and in 
acute myocardial infarction [17, 48], and in general, by low-
ered levels of HDL-c and apoA1, the latter being described 
as a potential PGI2-stabilising factor [17]. Our findings sug-
gest that in all such conditions important information about 
the thrombophilic status of a patient will be overlooked if 
platelet aggregability is not tested immediately after blood 
collection ("near patient measurement"). 
STUDY LIMITATIONS 
  The results of this study are based on experiments with a 
limited number of healthy non-smoking male subjects under 
controlled conditions. They did not use drugs for at least two 
weeks  before enrolment, and did not exercise, eat fish or 
drink alcohol within the 12 hours before the experiment, and 
the effect of circadian variation in platelet aggregability was 
minimised by starting all experiments at 11.00 h am. It re-
mains to be demonstrated that the enhancing effect of COX-
2 inhibition on platelet aggregability is also present in 
women, and in less controlled conditions.  
  To demonstrate that the effect of COX-2 inhibition on 
platelet aggregability in-vitro can only be observed when 
platelet aggregability is tested immediately after blood   
collection, only one agonist (ADP) was used, because our 
aggregometer had only one channel. The experiments might 
be repeated with other platelet agonists. 
CONCLUSION 
  Reduction of endogenous PGI2 by intake of selective or 
nonselective COX-2 inhibitors enhances ADP-induced plate-
let aggregation in humans. This can be demonstrated when 
aggregation is measured during the first minutes after blood 
withdrawal, but not one hour later. The results imply, first, 
that the level of endogenous PGI2 is sufficiently high to con-
tinuously reduce platelet aggregation under basal conditions; 
second, that the enhancement of aggregability by COX-2 
inhibition does not necessarily depend on increased TXA2 
activity; and, third, that important information about the 
thrombotic risk of a patient may be missed when aggregation 
is not measured immediately after venipuncture. Our results 
underline the concept that use of COX-2 inhibitors increases 
the risk for cardiovascular events by creating a prothrom-
botic environment.  
Table 2.  Literature Data on Mean Basal Levels of Plasma 6-keto-PGF1 
Method  Subjects  Mean Plasma 6-keto-PGF1 (pg/ml)  Ref. 
healthy adults   291, 245, 182, 161, 126, 115, 110, 88, 85, 26   [i-x] 
RIA 
patients before surgery  225, 154, 96, 53, 97, 46, 72, 109, 120  [xi-xix] 
RIA after separation 
on charcoal or HPLC 
healthy adults  <7.5, 4.7, 1.7, 1  [xx-xxiii] 
healthy adults  165, 297, 149, 145, 39, 38   [xxiv-xxix] 
ELISA 
patients before surgery  200, 57   [xxx, xxxi] 
RIA: radioimmunoassay. HPLC: High Performance Liquid Chromatography. ELISA: Enzyme-Linked Immuno Sorbent Assay. For references see APPENDIX 204    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Borgdorff
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